Developer docs
API playgroundTry for free, no card

Search company profiles

Cyclenium Pharma

Full company profile

uuid000cyvh

Namestring
Cyclenium Pharma
Legal namestring
Cyclenium Pharma Inc.
Websiteurl
cyclenium.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Cyclenium Pharma Inc. is a privately held Montreal-based Contract Research Organization (CRO) specializing in macrocyclic drug discovery, founded between 2013 and 2015 by former management and research staff of Tranzyme Pharma following Tranzyme's merger with Ocera Therapeutics (now part of Mallinckrodt Plc) and the closure of its Canadian R&D site. In May 2023, the company was acquired by SpiroChem AG (Switzerland) — co-founded in 2011 by Cyclenium's current CEO Thomas Fessard — and now operates as SpiroChem's wholly-owned Canadian subsidiary.

The company's core asset is its proprietary CMRT™ (Customized Macrocycles for Recognition of Topologies) chemistry platform, supported by the QUEST Library of 50,000+ synthetic macrocyclic compounds and a modular synthesis methodology designed to deliver macrocyclic drug candidates with drug-like properties, specifically oral bioavailability and blood-brain barrier penetration. The platform is positioned to address targets traditionally considered difficult or undruggable, particularly protein-protein interactions. Leadership includes co-founders Helmut Thomas and Mark L. Peterson (now advisors) carrying 130+ and 85+ scientific publications respectively, with Peterson's patent portfolio from Tranzyme exceeding 120 patents and applications. The internal pipeline comprises three named programs: broad-spectrum anti-flaviviral inhibitors (funded in part by a May 2020 U.S. Department of Defense grant), a cystic fibrosis novel-target program, and biased-signaling opioid receptor agonists for PTSD and anxiety disorders.

Cyclenium's business model rests on three revenue streams: collaborative drug discovery agreements with pharmaceutical and biotechnology partners (e.g., Ono Pharmaceutical Japan, AiCuris Germany, Haplogen Austria, Vuja De Sciences U.S., Hospital for Sick Children Toronto), contract research services using the CMRT platform and QUEST library on a fee-for-service basis, and out-licensing of proprietary pipeline programs alongside in-licensing of complementary assets. Engagement terms are negotiated on a bespoke, quote-based, multi-year basis; pricing is not publicly disclosed. The company has 1-10 employees, has received grant funding from FFG, NRC IRAP, EUREKA, and the U.S. Department of Defense, and operates with a global reach spanning North America, Europe, and Asia.

Short descriptiontext

Cyclenium Pharma is a Montreal-based Contract Research Organization specializing in macrocyclic drug discovery, deploying its proprietary CMRT™ platform and 50,000+ compound QUEST library to deliver orally bioavailable, blood-brain-barrier-penetrant drug candidates against challenging targets for pharmaceutical, biotechnology, and academic partners worldwide, operating as a wholly-owned subsidiary of SpiroChem AG.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMontreal, Canada
HQ citystring
Montreal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
macrocyclic drug discovery, contract research services, medicinal chemistry services, small molecule therapeutics, drug discovery platform
Industry3 codes
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Contract Research / Drug Discovery Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Discovery Collaborations & Out-Licensing
TypeLicensing Royalties
Description

Revenue generated through collaborative drug discovery agreements with pharmaceutical and biotech partners (e.g., Vuja De Sciences, AiCuris, Haplogen Biosciences, Ono Pharmaceutical) that combine research fees, milestone payments, and potential royalties/out-licensing of proprietary pipeline programs (anti-flaviviral, cystic fibrosis, opioid receptor agonists).

cyclenium.com
2Contract Research Services
TypeProfessional Services
Description

Provision of contract research and custom macrocyclic chemistry services leveraging the CMRT platform and QUEST library to support external drug discovery programs on a project/fee-for-service basis.

cyclenium.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Quote-based bespoke engagement for drug discovery collaborations and contract research services
ModelOtherBilling cadenceMulti-year contract
Notes

No pricing publicly disclosed; engagement terms negotiated per program with research fees, milestones, and potential royalties.

cyclenium.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Cyclenium Pharma is a Contract Research Organization (CRO) that deploys its proprietary CMRT (Customized Macrocycles for Recognition of Topologies) chemistry platform — supported by the QUEST screening library of 50,000+ synthetic macrocyclic compounds — to deliver macrocyclic drug discovery services to pharmaceutical and biotechnology companies. The company provides hit identification, lead optimization, and medicinal chemistry services, while also advancing an internal pipeline of macrocyclic therapeutic programs (anti-flaviviral, cystic fibrosis, opioid receptor agonists) available for out-licensing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • QUEST screening library of 50,000+ synthetic macrocyclic compounds enables broad hit-identification coverage
+1 more record
Product overview1 text field

Cyclenium Pharma is a Contract Research Organization (CRO) and macrocyclic drug discovery company organized around a single proprietary platform — its CMRT™ (Customized Macrocycles for Recognition of Topologies) technology — which serves as the core engine that powers both its internal pipeline and partner-facing offerings. The CMRT platform is supported by the QUEST Library, a proprietary macrocyclic compound collection used for high-throughput screening, and feeds the Collaborative Drug Discovery Services that Cyclenium offers to partners as a CRO. Output from the platform is also advanced into discrete out-licensing programs (broad-spectrum anti-flaviviral agents, a cystic fibrosis novel-target program, and biased-signaling opioid receptor agonists for PTSD and anxiety disorders), while an In-Licensing Opportunities function rounds out the portfolio by bringing in external assets. Together, the CMRT platform, QUEST Library, discovery services, out-licensing programs, and in-licensing function form a single integrated architecture in which the platform and library generate chemical matter and leads that are either progressed internally, partnered through the CRO services, or made available to other companies via out-licensing.

Product and service7 records
1CMRT Technology (Customized Macrocycles for Recognition of Topologies)
CategoryCore proprietary drug discovery platform
Description

Proprietary macrocyclic chemistry platform that enables the discovery and optimization of novel macrocyclic drug candidates with drug-like properties including oral bioavailability and blood-brain barrier penetration. The technology powers Cyclenium's internal pipeline and collaborative drug discovery programs for pharmaceutical and biotechnology partners.

2QUEST Library
CategoryCompound library / screening asset
Description

Proprietary macrocyclic compound library of 50,000+ synthetic macrocyclic compounds designed for high-throughput screening against biological targets, providing the chemical matter that feeds into the CMRT discovery workflow.

3Collaborative Drug Discovery Services
CategoryContract Research Organization (CRO) services
Description

Full-service macrocyclic drug discovery offerings provided to partners as a Contract Research Organization (CRO), covering hit identification, lead optimization, and medicinal chemistry, leveraging the CMRT platform and QUEST Library.

4Broad spectrum anti-flaviviral agents program
CategoryOut-licensing program / internal pipeline asset
Description

Preclinical macrocyclic program targeting broad-spectrum anti-flaviviral activity, available for out-licensing to partners.

5Cystic fibrosis novel target program
CategoryOut-licensing program / internal pipeline asset
Description

Discovery program applying the CMRT platform to a novel target strategy for cystic fibrosis, with assets available for out-licensing to partners.

6Biased signaling opioid receptor agonist program
CategoryOut-licensing program / internal pipeline asset
Description

Discovery effort focused on biased-signaling opioid receptor agonists being developed for the treatment of PTSD and anxiety disorders, available for out-licensing.

7In-Licensing Opportunities
CategoryBusiness development / licensing offering
Description

Program through which Cyclenium evaluates and in-licenses external macrocyclic and complementary small-molecule assets to expand its pipeline and partnership portfolio.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-05-01
Description

SpiroChem AG (Switzerland) acquired Cyclenium Pharma in May 2023, making Cyclenium a wholly-owned subsidiary. SpiroChem provides chemistry infrastructure and capital backing for ongoing R&D and partnerships.

2Vuja De Sciences
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-05
Description

Drug discovery collaboration announced January 5, 2022 with U.S.-based Vuja De Sciences for macrocyclic drug discovery leveraging the CMRT platform.

cyclenium.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-10-01
Description

Drug discovery collaboration announced October 1, 2018 with German anti-infective company AiCuris to identify macrocyclic anti-infective candidates.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-09-01
Description

Collaboration on pan-flaviviral therapeutics announced September 2018; project received EUREKA label status recognizing it as an internationally collaborative R&D effort.

5Ono Pharmaceutical (Japan)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-12-12
Description

Drug discovery collaboration announced December 12, 2017 with Japanese pharmaceutical company Ono Pharmaceutical.

cyclenium.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-03-07
Description

Research agreement announced March 7, 2017 with The Hospital for Sick Children in Toronto to support collaborative research using the CMRT platform.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Discovery services arm of Eurofins offering medicinal chemistry, in vitro pharmacology, ADME, and related services. Comparable to Cyclenium as a competing provider of chemistry-driven drug discovery services to pharma and biotech.

TypeBroad incumbent
Description

Major global CRO providing drug discovery, safety assessment, and manufacturing services. Comparable as an established contract research provider whose Discovery Services segment competes for the same pharma/biotech chemistry and discovery outsourcing budgets that Cyclenium targets.

TypeBroad incumbent
Description

Large CRO offering a full suite of drug discovery and development services including medicinal chemistry, in vitro biology, and DMPK. Comparable as a competing CRO that pharma/biotech can engage instead of Cyclenium for outsourced discovery work.

4Tranzyme Pharma (predecessor)
TypeOthers
Description

Predecessor organization of Cyclenium, founded by the same team, which pioneered macrocyclic chemistry and 50,000+ compound screening libraries. Comparable as the historical reference point for Cyclenium's technology and team lineage, though it no longer exists as an independent operating company.

TypeBroad incumbent
Description

Global CRO/CDMO offering comprehensive drug discovery and development services including medicinal chemistry, custom synthesis, and library synthesis. Comparable as a competing provider of contract chemistry services to pharma and biotech, though at vastly greater scale and with a broader modality footprint than Cyclenium.

TypeEmerging player
Description

UK-based CRO offering integrated drug discovery services including medicinal chemistry, in vitro biology, and ADME. Comparable to Cyclenium as a small-to-mid sized specialized CRO that competes for pharma/biotech discovery contracts with chemistry-centric services.

TypeDirect peer
Description

Provider of innovative building blocks, custom synthesis, and drug discovery services with deep expertise in scaffold chemistry. Comparable to Cyclenium as a chemistry-focused CRO serving pharma/biotech partners with specialized chemical matter and discovery capabilities.

TypeDirect peer
Description

India-based CRO/CDMO offering drug discovery, custom synthesis, and development services. Comparable to Cyclenium as a mid-sized chemistry CRO serving global pharma partners with contract discovery and medicinal chemistry capabilities.

TypeDirect peer
Description

China-based CRO providing integrated drug discovery services with strength in medicinal chemistry, custom synthesis, and biology. Comparable to Cyclenium as a similarly-sized chemistry-focused CRO serving global pharma and biotech partners with discovery services.

TypeBroad incumbent
Description

Parent company of Cyclenium Pharma and a Swiss fine chemicals company specializing in building blocks, scaffolds, and process chemistry. It is directly comparable as it shares the same founder/CEO (Thomas Fessard) and now operates the CMRT platform through its Cyclenium subsidiary.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cyclenium Pharma

Contract Research / Drug Discovery Servicescyclenium.com

Cyclenium Pharma is a Montreal-based Contract Research Organization specializing in macrocyclic drug discovery, deploying its proprietary CMRT™ platform and 50,000+ compound QUEST library to deliver orally bioavailable, blood-brain-barrier-penetrant drug candidates against challenging targets for pharmaceutical, biotechnology, and academic partners worldwide, operating as a wholly-owned subsidiary of SpiroChem AG.

What Cyclenium Pharma does

Cyclenium Pharma Inc. is a privately held Montreal-based Contract Research Organization (CRO) specializing in macrocyclic drug discovery, founded between 2013 and 2015 by former management and research staff of Tranzyme Pharma following Tranzyme's merger with Ocera Therapeutics (now part of Mallinckrodt Plc) and the closure of its Canadian R&D site. In May 2023, the company was acquired by SpiroChem AG (Switzerland) — co-founded in 2011 by Cyclenium's current CEO Thomas Fessard — and now operates as SpiroChem's wholly-owned Canadian subsidiary.

The company's core asset is its proprietary CMRT™ (Customized Macrocycles for Recognition of Topologies) chemistry platform, supported by the QUEST Library of 50,000+ synthetic macrocyclic compounds and a modular synthesis methodology designed to deliver macrocyclic drug candidates with drug-like properties, specifically oral bioavailability and blood-brain barrier penetration. The platform is positioned to address targets traditionally considered difficult or undruggable, particularly protein-protein interactions. Leadership includes co-founders Helmut Thomas and Mark L. Peterson (now advisors) carrying 130+ and 85+ scientific publications respectively, with Peterson's patent portfolio from Tranzyme exceeding 120 patents and applications. The internal pipeline comprises three named programs: broad-spectrum anti-flaviviral inhibitors (funded in part by a May 2020 U.S. Department of Defense grant), a cystic fibrosis novel-target program, and biased-signaling opioid receptor agonists for PTSD and anxiety disorders.

Cyclenium's business model rests on three revenue streams: collaborative drug discovery agreements with pharmaceutical and biotechnology partners (e.g., Ono Pharmaceutical Japan, AiCuris Germany, Haplogen Austria, Vuja De Sciences U.S., Hospital for Sick Children Toronto), contract research services using the CMRT platform and QUEST library on a fee-for-service basis, and out-licensing of proprietary pipeline programs alongside in-licensing of complementary assets. Engagement terms are negotiated on a bespoke, quote-based, multi-year basis; pricing is not publicly disclosed. The company has 1-10 employees, has received grant funding from FFG, NRC IRAP, EUREKA, and the U.S. Department of Defense, and operates with a global reach spanning North America, Europe, and Asia.

Cyclenium Pharma firmographics

Firmographics
Name
Cyclenium Pharma
Legal name
Cyclenium Pharma Inc.
Website
https://cyclenium.com
Company type
Private
Founded year
2013
Operating status
Acquired
Headcount range
11–50 employees
Short description
Cyclenium Pharma is a Montreal-based Contract Research Organization specializing in macrocyclic drug discovery, deploying its proprietary CMRT™ platform and 50,000+ compound QUEST library to deliver orally bioavailable, blood-brain-barrier-penetrant drug candidates against challenging targets for pharmaceutical, biotechnology, and academic partners worldwide, operating as a wholly-owned subsidiary of SpiroChem AG.
Ownership category
akta.pro rank

Cyclenium Pharma industry classification

Industry
Product category
Contract Research / Drug Discovery Services
NAICS
Scientific Research and Development Services (5417), Medicinal and Botanical Manufacturing (325411)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Macrocyclic drug discovery
  • Contract research services
  • Medicinal chemistry services
  • Small molecule therapeutics
  • Drug discovery platform

Where Cyclenium Pharma is headquartered

Location

Headquarters

HQ city
Montreal
HQ country
Canada
HQ region
North America

Markets served

Cyclenium Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Discovery Collaborations & Out-Licensing: Revenue generated through collaborative drug discovery agreements with pharmaceutical and biotech partners (e.g., Vuja De Sciences, AiCuris, Haplogen Biosciences, Ono Pharmaceutical) that combine research fees, milestone payments, and potential royalties/out-licensing of proprietary pipeline programs (anti-flaviviral, cystic fibrosis, opioid receptor agonists).
  2. Contract Research Services: Provision of contract research and custom macrocyclic chemistry services leveraging the CMRT platform and QUEST library to support external drug discovery programs on a project/fee-for-service basis.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based bespoke engagement for drug discovery collaborations and contract research services

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Cyclenium Pharma product offering

Product offering

Core offering

Cyclenium Pharma is a Contract Research Organization (CRO) that deploys its proprietary CMRT (Customized Macrocycles for Recognition of Topologies) chemistry platform — supported by the QUEST screening library of 50,000+ synthetic macrocyclic compounds — to deliver macrocyclic drug discovery services to pharmaceutical and biotechnology companies. The company provides hit identification, lead optimization, and medicinal chemistry services, while also advancing an internal pipeline of macrocyclic therapeutic programs (anti-flaviviral, cystic fibrosis, opioid receptor agonists) available for out-licensing.

Product overview

Cyclenium Pharma is a Contract Research Organization (CRO) and macrocyclic drug discovery company organized around a single proprietary platform — its CMRT™ (Customized Macrocycles for Recognition of Topologies) technology — which serves as the core engine that powers both its internal pipeline and partner-facing offerings. The CMRT platform is supported by the QUEST Library, a proprietary macrocyclic compound collection used for high-throughput screening, and feeds the Collaborative Drug Discovery Services that Cyclenium offers to partners as a CRO. Output from the platform is also advanced into discrete out-licensing programs (broad-spectrum anti-flaviviral agents, a cystic fibrosis novel-target program, and biased-signaling opioid receptor agonists for PTSD and anxiety disorders), while an In-Licensing Opportunities function rounds out the portfolio by bringing in external assets. Together, the CMRT platform, QUEST Library, discovery services, out-licensing programs, and in-licensing function form a single integrated architecture in which the platform and library generate chemical matter and leads that are either progressed internally, partnered through the CRO services, or made available to other companies via out-licensing.

Differentiator

Problem solved

Functional benefit

Products and services

  • CMRT Technology (Customized Macrocycles for Recognition of Topologies) Proprietary macrocyclic chemistry platform that enables the discovery and optimization of novel macrocyclic drug candidates with drug-like properties including oral bioavailability and blood-brain barrier penetration. The technology powers Cyclenium's internal pipeline and collaborative drug discovery programs for pharmaceutical and biotechnology partners.
  • QUEST Library Proprietary macrocyclic compound library of 50,000+ synthetic macrocyclic compounds designed for high-throughput screening against biological targets, providing the chemical matter that feeds into the CMRT discovery workflow.
  • Collaborative Drug Discovery Services Full-service macrocyclic drug discovery offerings provided to partners as a Contract Research Organization (CRO), covering hit identification, lead optimization, and medicinal chemistry, leveraging the CMRT platform and QUEST Library.
  • Broad spectrum anti-flaviviral agents program Preclinical macrocyclic program targeting broad-spectrum anti-flaviviral activity, available for out-licensing to partners.
  • Cystic fibrosis novel target program Discovery program applying the CMRT platform to a novel target strategy for cystic fibrosis, with assets available for out-licensing to partners.
  • Biased signaling opioid receptor agonist program Discovery effort focused on biased-signaling opioid receptor agonists being developed for the treatment of PTSD and anxiety disorders, available for out-licensing.
  • In-Licensing Opportunities Program through which Cyclenium evaluates and in-licenses external macrocyclic and complementary small-molecule assets to expand its pipeline and partnership portfolio.

Quantifiable outcome

  • QUEST screening library of 50,000+ synthetic macrocyclic compounds enables broad hit-identification coverage
  • +1 more outcomes

Companies that use Cyclenium Pharma

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Cyclenium Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cyclenium Pharma partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship, core and minor.

  • SpiroChem AGflagshipStrategic or Co-development Partner · 1 May 2023SpiroChem AG (Switzerland) acquired Cyclenium Pharma in May 2023, making Cyclenium a wholly-owned subsidiary. SpiroChem provides chemistry infrastructure and capital backing for ongoing R&D and partnerships.
  • Vuja De SciencescoreStrategic or Co-development Partner · 5 January 2022Drug discovery collaboration announced January 5, 2022 with U.S.-based Vuja De Sciences for macrocyclic drug discovery leveraging the CMRT platform.
  • AiCuris (Germany)coreStrategic or Co-development Partner · 1 October 2018Drug discovery collaboration announced October 1, 2018 with German anti-infective company AiCuris to identify macrocyclic anti-infective candidates.
  • Haplogen Biosciences (Austria)coreStrategic or Co-development Partner · 1 September 2018Collaboration on pan-flaviviral therapeutics announced September 2018; project received EUREKA label status recognizing it as an internationally collaborative R&D effort.
  • Ono Pharmaceutical (Japan)coreStrategic or Co-development Partner · 12 December 2017Drug discovery collaboration announced December 12, 2017 with Japanese pharmaceutical company Ono Pharmaceutical.
  • Hospital for Sick Children (SickKids), TorontominorStrategic or Co-development Partner · 7 March 2017Research agreement announced March 7, 2017 with The Hospital for Sick Children in Toronto to support collaborative research using the CMRT platform.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Cyclenium Pharma competitors and assessment

Company assessment

Broad incumbents

  • Eurofins Discovery: Discovery services arm of Eurofins offering medicinal chemistry, in vitro pharmacology, ADME, and related services. Comparable to Cyclenium as a competing provider of chemistry-driven drug discovery services to pharma and biotech.
  • Charles River Laboratories: Major global CRO providing drug discovery, safety assessment, and manufacturing services. Comparable as an established contract research provider whose Discovery Services segment competes for the same pharma/biotech chemistry and discovery outsourcing budgets that Cyclenium targets.
  • Labcorp Drug Development (Fortrea): Large CRO offering a full suite of drug discovery and development services including medicinal chemistry, in vitro biology, and DMPK. Comparable as a competing CRO that pharma/biotech can engage instead of Cyclenium for outsourced discovery work.
  • WuXi AppTec: Global CRO/CDMO offering comprehensive drug discovery and development services including medicinal chemistry, custom synthesis, and library synthesis. Comparable as a competing provider of contract chemistry services to pharma and biotech, though at vastly greater scale and with a broader modality footprint than Cyclenium.
  • SpiroChem AG: Parent company of Cyclenium Pharma and a Swiss fine chemicals company specializing in building blocks, scaffolds, and process chemistry. It is directly comparable as it shares the same founder/CEO (Thomas Fessard) and now operates the CMRT platform through its Cyclenium subsidiary.

Others

  • Tranzyme Pharma (predecessor): Predecessor organization of Cyclenium, founded by the same team, which pioneered macrocyclic chemistry and 50,000+ compound screening libraries. Comparable as the historical reference point for Cyclenium's technology and team lineage, though it no longer exists as an independent operating company.

Emerging players

  • Domainex: UK-based CRO offering integrated drug discovery services including medicinal chemistry, in vitro biology, and ADME. Comparable to Cyclenium as a small-to-mid sized specialized CRO that competes for pharma/biotech discovery contracts with chemistry-centric services.

Direct peers

  • PharmaBlock Sciences: Provider of innovative building blocks, custom synthesis, and drug discovery services with deep expertise in scaffold chemistry. Comparable to Cyclenium as a chemistry-focused CRO serving pharma/biotech partners with specialized chemical matter and discovery capabilities.
  • Sai Life Sciences: India-based CRO/CDMO offering drug discovery, custom synthesis, and development services. Comparable to Cyclenium as a mid-sized chemistry CRO serving global pharma partners with contract discovery and medicinal chemistry capabilities.
  • ChemPartner: China-based CRO providing integrated drug discovery services with strength in medicinal chemistry, custom synthesis, and biology. Comparable to Cyclenium as a similarly-sized chemistry-focused CRO serving global pharma and biotech partners with discovery services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Cyclenium Pharma social profiles

Digital presence

Cyclenium Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cyclenium Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Cyclenium Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cyclenium Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cyclenium Pharma

What does Cyclenium Pharma do?

Cyclenium Pharma is a Contract Research Organization (CRO) that deploys its proprietary CMRT (Customized Macrocycles for Recognition of Topologies) chemistry platform — supported by the QUEST screening library of 50,000+ synthetic macrocyclic compounds — to deliver macrocyclic drug discovery services to pharmaceutical and biotechnology companies. The company provides hit identification, lead optimization, and medicinal chemistry services, while also advancing an internal pipeline of macrocyclic therapeutic programs (anti-flaviviral, cystic fibrosis, opioid receptor agonists) available for out-licensing.

Is Cyclenium Pharma a public or private company?

Cyclenium Pharma is a private company. It is classified as corporate owned and is currently acquired.

When was Cyclenium Pharma founded?

Cyclenium Pharma was founded in 2013. It employs 11 to 50 people.

Where is Cyclenium Pharma based?

Cyclenium Pharma is headquartered in Montreal, Canada, in the North America region.

How does Cyclenium Pharma make money?

Two revenue lines are on record. Drug Discovery Collaborations & Out-Licensing is the primary driver. The others are contract Research Services.

Who are Cyclenium Pharma's main competitors?

Broad incumbents on record are Eurofins Discovery, Charles River Laboratories, Labcorp Drug Development (Fortrea), WuXi AppTec and SpiroChem AG. Tranzyme Pharma (predecessor) is listed as an others. Domainex is listed as an emerging player. Direct peers are PharmaBlock Sciences, Sai Life Sciences and ChemPartner.

Does Cyclenium Pharma have an API?

No public API is recorded for Cyclenium Pharma.

What industry is Cyclenium Pharma in?

Cyclenium Pharma's product category is Contract Research / Drug Discovery Services. Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAGAAAH, Pharmacovigilance, Risk Management & Medical Affairs CROs. Its NAICS code is 5417 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals